Effect of Number of Bifunctional Chelating Agents on the Pharmacokinetics and Immunoreactivity of 177Lu-labeled Rituximab: A Systemic Study
Mohini Guleria(Bhabha Atomic Research Centre), Ashutosh Dash(Bhabha Atomic Research Centre), Rohit Sharma(Shoolini University), Tapas Das(Bhabha Atomic Research Centre), Jeyachitra Amirdhanayagam(Bhabha Atomic Research Centre), Chandan Kumar(University of Michigan), Haladhar Dev Sarma(Bhabha Atomic Research Centre)
Cited by 17
Related Papers
Production of 177Lu for Targeted Radionuclide Therapy: Available Options
|Nuclear Medicine and Molecular Imaging|2015|375
Sustained Availability of <sup>99m</sup>Tc: Possible Paths Forward
|Journal of Nuclear Medicine|2012|140
Peptide Receptor Radionuclide Therapy: An Overview
|Cancer Biotherapy and Radiopharmaceuticals|2015|122
Targeted Radionuclide Therapy - An Overview
|Current Radiopharmaceuticals|2013|117
Development of an electrochemical 90Sr–90Y generator for separation of 90Y suitable for targeted therapy
|Nuclear Medicine and Biology|2008|99